Submission of intimation of preferential issue of equity shares.

Fund Raising View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹98.60

prior close

₹98.96

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-1.7% vs market

Pharmaceuticals peers, median of 152sector+0.3%-1.3% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.3

15m

-1.3

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0+0.7-1.7+0.3-1.3

Next day

-1.6+0.1-1.7-0.5-1.1

-1.2-1.0-0.2-1.4+0.2

+1.3-0.0+1.3-1.0+2.3

+1.4+0.5+0.9-0.6+2.0

+1.3+0.0+1.3-1.0+2.3

+2.3+2.1+0.3+0.1+2.3

15d

-0.7+2.9-3.6+0.3-1.0

-4.2+0.4-4.6-2.1-2.1

-18.9-5.0-13.9-5.8-13.1

-12.0-7.1-4.9-8.8-3.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astal Laboratories' board, on October 9, 2025, approved issuing 3,04,58,187 equity shares at Rs. 91 each (face value Rs. 10 + premium of Rs. 81), aggregating to about Rs. 277.17 crore. These shares will be allotted to 135 shareholders of Sriven Pharmachem India Private Limited as consideration other than cash, i.e. in exchange for acquiring 100% of Sriven Pharmachem's equity. This is a share-swap (stock-for-stock) acquisition, not a cash deal, and is routed through a preferential allotment under SEBI ICDR regulations. The issue is subject to shareholder approval at an Extra-Ordinary General Meeting and other regulatory clearances.

Likely market impact

Existing shareholders of Astal Laboratories will face significant dilution as over 3 crore new shares (at Rs. 91) will be issued, expanding the equity base materially. The deal is non-cash, so it does not strain liquidity, but success depends on Sriven Pharmachem turning out to be a value-accretive acquisition; the share price could react once the swap ratio and target's financials are assessed.